Laura Bush, DMSc, PA-C, DFAAPA

Closing the series, the panel offers concrete advice for recognizing HS earlier and building the confidence to escalate therapy before patients reach advanced, disabling disease.

As oral therapies near approval, the panel considers whether they belong first-line, second-line, or both, and how expanding options could finally support earlier HS treatment escalation.

New trial data on povorcitinib, upadacitinib, and remibrutinib show meaningful HiSCR responses and reassuring cardiovascular safety. The panel discusses how to present this evidence to patients.

JAK and BTK inhibitors approach HS inflammation from different angles inside the cell. Laura Bush breaks down how each emerging oral therapy interrupts the disease process.

Not every flare signals treatment failure. The panel distinguishes manageable fluctuations from true loss of response and weighs how comorbidities and insurance shape next-line biologic selection.

A second patient, initially helped by adalimumab, shows how HS can outpace a first-line biologic over time. The panel discusses recognizing secondary failure and rebuilding a treatment plan.

Setting realistic timelines and reading quality of life matter as much as counting lesions. The panel also flags a common pitfall: mistaking healing pigment changes for active disease.

Black box warnings, screening requirements, and real-world experience all shape which biologic fits a given patient. The panel applies these safety considerations directly to the first case.

Adalimumab, secukinumab, and bimekizumab each carry distinct trial populations and response rates. The panel reviews years of efficacy and safety data behind today's approved HS biologics.

A 29-year-old with years of axillary and groin disease illustrates how psychosocial toll, not just visible lesions, should guide the decision to escalate beyond conventional HS therapy.

Three FDA-approved biologics now intercept the inflammatory cascade at different points, yet Dr. Laura Bush argues a calm exam can understate real disease burden. The panel discusses when history should outweigh appearance.

Hidradenitis suppurativa often goes undiagnosed for years while patients quietly absorb pain, odor, and isolation. The panel examines why recognizing these signals early changes everything that follows.

Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.

Aubrie Jones, PA-C, MMS, and Laura Bush, DMSc, PA-C, DFAAPA, discuss the role of the SDPA in supporting the growth and journeys of PAs at all stages.

SDPA President Laura Bush DMSc, PA-C, DFAAPA, shares exciting news about the name change as the Summer Conference begins to wind down.

Laura Bush, DMSc, PA-C, DFAAPA, talks to Renata Block, MMS, PA-C, about her SDPA presidency, the future, and the importance of a positive outlook.

The work we do as caregivers is important, and it's equally important that we take care of ourselves.

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.

Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.

Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.

Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Laura Bush, DMSc, PA-C, provides an overview of systemic treatment options for patients with plaque psoriasis, highlighting the follow-up process once treatment has been implemented.

Jennifer Conner, MPAS, PA-C, and Lakshi Aldredge, MSN, ANP-BC, comment on approaches to escalating treatment of plaque psoriasis from topical therapy to systemic therapy and initiating that conversation with the patient.

Experts in dermatology review a case of a patient with plaque psoriasis concentrated on her hands and discuss taking the patient’s preferences into consideration when selecting treatment.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, discuss metrics to determine clearance in plaque psoriasis and how the provider’s expectations may be different from the patient’s expectations.